WO2021203661A1 - 一种辅助降脂减肥的海藻果蔬配方 - Google Patents
一种辅助降脂减肥的海藻果蔬配方 Download PDFInfo
- Publication number
- WO2021203661A1 WO2021203661A1 PCT/CN2020/120760 CN2020120760W WO2021203661A1 WO 2021203661 A1 WO2021203661 A1 WO 2021203661A1 CN 2020120760 W CN2020120760 W CN 2020120760W WO 2021203661 A1 WO2021203661 A1 WO 2021203661A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- assisting
- hijiki
- extract
- seaweed
- Prior art date
Links
- 241001474374 Blennius Species 0.000 title abstract description 15
- 235000012055 fruits and vegetables Nutrition 0.000 title abstract description 13
- 229940052016 turmeric extract Drugs 0.000 claims abstract description 25
- 239000008513 turmeric extract Substances 0.000 claims abstract description 25
- 241000219991 Lythraceae Species 0.000 claims abstract description 7
- 235000014360 Punica granatum Nutrition 0.000 claims abstract description 7
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 30
- 235000020240 turmeric extract Nutrition 0.000 claims description 23
- 239000001575 punica granatum l. bark extract Substances 0.000 claims description 21
- 235000012754 curcumin Nutrition 0.000 claims description 15
- 229940109262 curcumin Drugs 0.000 claims description 15
- 239000004148 curcumin Substances 0.000 claims description 15
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 15
- 235000005911 diet Nutrition 0.000 claims description 8
- 230000037213 diet Effects 0.000 claims description 8
- 230000004580 weight loss Effects 0.000 claims description 8
- 230000000694 effects Effects 0.000 abstract description 24
- 239000000284 extract Substances 0.000 abstract description 9
- 241000264279 Sargassum fusiforme Species 0.000 abstract description 5
- 230000036541 health Effects 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 235000003392 Curcuma domestica Nutrition 0.000 abstract description 3
- 229930014626 natural product Natural products 0.000 abstract description 3
- 239000013543 active substance Substances 0.000 abstract description 2
- 231100000252 nontoxic Toxicity 0.000 abstract description 2
- 230000003000 nontoxic effect Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 241000283690 Bos taurus Species 0.000 abstract 2
- 244000163122 Curcuma domestica Species 0.000 abstract 2
- 241000699670 Mus sp. Species 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 230000004044 response Effects 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 208000008589 Obesity Diseases 0.000 description 7
- 229920000241 Punicalagin Polymers 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 238000013116 obese mouse model Methods 0.000 description 7
- 235000020824 obesity Nutrition 0.000 description 7
- ZJVUMAFASBFUBG-OGJBWQGYSA-N punicalagin Chemical compound C([C@H]1O[C@@H]([C@@H]2OC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)O[C@H]2[C@@H]1OC(=O)C1=CC(O)=C(O)C(O)=C11)O)OC(=O)C2=CC(O)=C(O)C(O)=C2C2=C(O)C(O)=C(OC3=O)C4=C2C(=O)OC2=C4C3=C1C(O)=C2O ZJVUMAFASBFUBG-OGJBWQGYSA-N 0.000 description 7
- LMIBIMUSUFYFJN-RSVYENFWSA-N punicalagin Natural products O[C@@H]1O[C@@H]2COC(=O)c3cc(O)c(O)c(O)c3c4c(O)cc5OC(=O)c6c(c(O)c(O)c7OC(=O)c4c5c67)c8c(O)c(O)c(O)cc8C(=O)O[C@H]2[C@@H]9OC(=O)c%10cc(O)c(O)c(O)c%10c%11c(O)c(O)c(O)cc%11C(=O)O[C@@H]19 LMIBIMUSUFYFJN-RSVYENFWSA-N 0.000 description 7
- ZRKSVMFLACVUIU-UHFFFAOYSA-N punicalagin isomer Natural products OC1=C(O)C(=C2C3=4)OC(=O)C=4C4=C(O)C(O)=C3OC(=O)C2=C1C1=C(O)C(O)=C(O)C=C1C(=O)OC1C2OC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(O)OC1COC(=O)C1=CC4=C(O)C(O)=C1O ZRKSVMFLACVUIU-UHFFFAOYSA-N 0.000 description 7
- 210000004003 subcutaneous fat Anatomy 0.000 description 7
- 208000016261 weight loss Diseases 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 201000010063 epididymitis Diseases 0.000 description 6
- 235000009200 high fat diet Nutrition 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 230000037356 lipid metabolism Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- XRHVZWWRFMCBAZ-UHFFFAOYSA-L Endothal-disodium Chemical compound [Na+].[Na+].C1CC2C(C([O-])=O)C(C(=O)[O-])C1O2 XRHVZWWRFMCBAZ-UHFFFAOYSA-L 0.000 description 3
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- 108010067035 Pancrelipase Proteins 0.000 description 3
- 230000035508 accumulation Effects 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 108010028144 alpha-Glucosidases Proteins 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000037353 metabolic pathway Effects 0.000 description 3
- 229940045258 pancrelipase Drugs 0.000 description 3
- 238000005211 surface analysis Methods 0.000 description 3
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 2
- 241000199919 Phaeophyceae Species 0.000 description 2
- 241000195474 Sargassum Species 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000000883 anti-obesity agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000006286 aqueous extract Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- SJWWTRQNNRNTPU-ABBNZJFMSA-N fucoxanthin Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C(=O)C[C@]1(C(C[C@H](O)C2)(C)C)[C@]2(C)O1 SJWWTRQNNRNTPU-ABBNZJFMSA-N 0.000 description 2
- AQLRNQCFQNNMJA-UHFFFAOYSA-N fucoxanthin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC(=CC=CC=C(/C)C=CC=C(/C)C(=O)CC23OC2(C)CC(O)CC3(C)C)C)CO)C(C)(O)C1 AQLRNQCFQNNMJA-UHFFFAOYSA-N 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 235000004213 low-fat Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 244000008991 Curcuma longa Species 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000020940 control diet Nutrition 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000576 food coloring agent Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000021393 food security Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000028503 regulation of lipid metabolic process Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 150000008494 α-glucosides Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the invention belongs to the technical field of health care, and specifically relates to a seaweed fruit and vegetable formula for assisting in reducing fat and losing weight.
- Seaweed is abundant in production and easy to obtain. It is a marine biological resource with dual-use value for food and medicine.
- many natural products from seaweeds have biological activities such as anti-inflammatory, lipid-lowering weight loss, and blood sugar-lowering.
- hijiki in brown algae has been studied extensively on its active ingredients and corresponding physiological functions; among them, there are articles mentioning that the fucoxanthin extract in hijiki can reduce blood sugar metabolism by regulating the metabolic pathways of blood sugar.
- the technical problem to be solved by the present invention is that hijiki can only significantly reduce epididymal fat, but has no effect on subcutaneous fat, and the effect of single consumption is not good. Therefore, a formula food is needed to make up for the deficiency of hijiki in fat reduction.
- the present invention provides a seaweed fruit and vegetable formula that assists in reducing fat and losing weight.
- turmeric extract and pomegranate peel extract in hijiki
- the natural active substances in seaweed and fruits and vegetables are fully utilized to achieve auxiliary reduction.
- the natural properties of seaweed fruits and vegetables will greatly reduce the toxic and side effects of synthetic substances.
- the natural products from which they are derived are safe, non-toxic and harmless, and can achieve the purpose of assisting in reducing fat and losing weight, and can improve the health of the population.
- a formula for assisting in reducing fat and losing weight including the following components by mass percentage: hijiki 95-96%; turmeric extract 2-3%; pomegranate peel extract ⁇ 1-2%.
- Sargassum fusiforme is a plant of the genus Sargassum in the Sargassum family of the Phaeophyta. It is distributed in coastal areas of China. It is a natural food with low fat, low heat, high protein, high dietary fiber and rich in mineral elements. Research has found that hijiki has a wide range of biological activities, such as antioxidant, anti-cancer and weight loss effects. Studies have shown that the fucoxanthin extract in hijiki has a good weight loss effect, and its mechanism of action is yet to be studied, but the experimental results indicate that it may reduce blood sugar content and achieve weight loss by regulating the blood sugar metabolism pathway.
- Curcumin is a common food coloring extracted from the ginger family plant turmeric, which has anti-oxidant and anti-inflammatory functions. Studies have shown that curcumin can also regulate lipid metabolism in the body and significantly reduce cholesterol levels in serum and liver. During lipid metabolism, part of the products will enter blood glucose metabolism through glycolysis or sugar production. The synergistic effect of curcumin on hijiki may lie in the regulation of lipid metabolism, which decomposes fat in the body, especially subcutaneous fat. Then it is metabolized through the blood sugar metabolic pathway, so as to solve the problem that hijiki can't act on subcutaneous fat.
- the turmeric extract used in the present invention is derived from Shaanxi Tengmai Biotechnology Co., Ltd., and its main component is curcumin, with a content of about 20%.
- pomegranate Glycosides After being absorbed by the human body, punicalagin, a polyphenolic substance extracted from pomegranate peel, can be decomposed into ellagic acid. It has excellent antioxidant properties and plays an important role in anti-inflammatory and anti-cancer aspects. At the same time, studies have shown that pomegranate Glycosides also have the effect of reducing fat and losing weight.
- the role of punicalagin in the formula may be to improve the inflammatory response and liver oxidative stress, strengthen the liver's conversion of cholesterol, and assist the cholesterol-lowering effect of curcumin, thereby affecting lipid metabolism; on the other hand, it may be Improve insulin resistance and reduce the glucose uptake capacity of cells, thereby assisting hijiki to improve blood sugar metabolism, so as to achieve the best effect of assisting in fat loss.
- the pomegranate peel extract used in the present invention is derived from Shaanxi Tengmai Biotechnology Co., Ltd., and its main component is punicarin, with a content of about 20%.
- the formula includes the following components in mass percentages: hijiki 95.88%; turmeric extract 2.68%; pomegranate peel extract 1.44%.
- the P value of the model is less than 0.05, which indicates that the model is significant; the p value of the model lack-of-fit item is greater than 0.05, indicating that the model lack-of-fit item is not significant.
- the model correlation coefficients R 2 of the two response values are 0.99 and 0.94, respectively. After correction, R 2 is 0.97 and 0.82, respectively, indicating that the model correlation is good; the coefficient of variation of the model is less than 10%, indicating that the model has good confidence in the response value , The model can better reflect the authenticity of the experiment.
- the response surface test data is analyzed and processed, and the results are shown in Table 3 and Figure 1.
- the inhibitory effect of the formula on the two enzymes is better than the levels of A2 and A3; at the level of B3 (curcumin), the formula is right
- the inhibitory effect of the two enzymes is better than that of B1 and B2; when the C3 level (puunicalagin), the inhibitory effect of the formula on the two enzymes is better than that of C1 and C2.
- the best formula is as follows: the ratio of the aqueous extract of hijiki is 150, the ratio of curcumin is 6; the ratio of punicalagin is 3; the corresponding model predicts ⁇ -glucoside
- the enzyme inhibition rate was 45.98%, and the pancrelipase inhibition rate was 73.88%.
- the ⁇ -glucosidase inhibition rate of the formula is 47.77 ⁇ 2.15%, and the pancreatic lipase inhibition rate is 74.18 ⁇ 0.46%, the actual value It is similar to the predicted value, indicating that the model can better predict the best formulation ratio.
- the purity of curcumin in this formula is 95%, and the purity of punicalagin is 98%.
- the ingredients in the formula are all high-purity functional factors, there is no habit of eating, it is not a new food material, and it cannot be used directly in health food.
- a health food-grade formula was formulated, in which the water extract of hijiki was corresponding to hijiki (the water extract content of hijiki was about 15%), and the curcumin was corresponding to the turmeric extract (the content of curcumin was about 20%).
- A The ratio of the water extract of Sargassum fusiforme
- B The ratio of curcumin
- C The ratio of punicalagin
- K1:1 level The ratio of the water extract of Sargassum fusiforme
- K2:2 level The ratio of curcumin
- K3:3 level The ratio of punicalagin
- curcumin content of the turmeric extract used in the formula is 20%
- punicalagin content of the pomegranate peel extract is 20%
- each component is weighed according to the mass percentage of the formula, and added to the diet at a ratio of 5%.
- the added amount of the test substance in the feed shall not exceed 5%, in order not to affect the normal diet structure. Therefore, it is added to the diet at a ratio of 5%, which can help lower blood lipids and relieve obesity without affecting the normal diet structure.
- the invention uses hijiki as the main raw material and utilizes the excellent natural resources of seaweed, fruits and vegetables to develop a seaweed, fruit and vegetable compound formula, which has a significant inhibitory effect on the weight gain of obese mice induced by a high-fat diet, and can reduce lipids in mice. Accumulate, reduce blood lipid levels, so as to assist in lowering blood lipids and alleviate obesity; and realize the high-value utilization of hijiki.
- Figure 1 Single factor and response surface analysis of seaweed, fruits and vegetables.
- the formula of this embodiment is 95% hijiki, 3% turmeric extract, and 2% pomegranate peel extract. Weigh each component according to the mass percentage of the formula, and add it to the diet at a 5% addition amount after mixing.
- the formula of this embodiment is 96% hijiki, 3% turmeric extract, and 1% pomegranate peel extract. Weigh each component according to the mass percentage of the formula, and add it to the diet at a 5% addition amount after mixing.
- the formula of this example is 96% hijiki, 2% turmeric extract, and 2% pomegranate peel extract. Weigh each component according to the mass percentage of the formula, and add it to the diet at a 5% addition amount after mixing.
- the formula of this embodiment is 95.5% of hijiki; turmeric extract 2.5%; pomegranate peel extract 2%. Weigh each component according to the mass percentage of the formula, and add it to the diet at a 5% addition amount after mixing.
- the formula of this embodiment is hijiki 95.88%; turmeric extract 2.68%; pomegranate peel extract 1.44%. Weigh each component according to the mass percentage of the formula, and add it to the diet at a 5% addition amount after mixing.
- mice were adaptively fed for 1 week and randomly divided into 6 groups according to their body weight, each with 10 mice, namely normal group (Control), obesity model group (Model), hijiki group (S), hijiki and Pomegranate peel extract compound group (SP), hijiki and turmeric extract compound group (ST), three-component formula group (STP).
- the mice in the normal group were given 10% low-fat control diet (D14060603), and the remaining 5 groups were given 45% high-fat diet (D14060606).
- the mice were free to eat for 9 weeks.
- the indoor temperature is 21°C-23°C, the relative humidity is 40%-55%, the air is circulating, and the light time is 12h.
- mice of each group were given the feed as shown in Table 4, and the feeding was continued for 4 weeks.
- the body weight was weighed once a week, and the food intake was recorded every 2 days.
- the body was weighed, sacrificed, and the corresponding internal organs were dissected, weighed and recorded, and stored at -80°C for later use.
- the formula of the present invention can significantly reduce the content of triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) in the blood of obese mice, and can restore the ratio of LDL-C:HDL-C to a normal level, and the effect is better than Hijiki menu one ingredient and two ingredients (mixed hijiki with turmeric extract or pomegranate peel extract). It shows that the formula of the present invention can help reduce the blood lipid level of obese mice.
- TG triglyceride
- LDL-C low-density lipoprotein cholesterol
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
一种辅助降脂减肥的海藻果蔬配方，包括以下质量百分比的组分：羊栖菜95-96％；姜黄提取物2-3％；石榴皮提取物1-2％。通过在羊栖菜中复配姜黄提取物和石榴皮提取物，充分利用海藻和果蔬中的天然活性物质，实现辅助降脂减肥的效果，并进一步提高自然资源的利用率。同时，海藻果蔬的天然属性会极大降低合成物质带来的毒副作用，其来源的天然产物安全无毒、无害，并且能够达到辅助降脂减肥的目的，能够改善人群的健康状况。
Description
本发明属于保健技术领域，具体涉及一种辅助降脂减肥的海藻果蔬配方。
据《世界粮食安全和营养状况》的数据，肥胖每年导致约400万人死亡，学龄段人群成为肥胖高发群体，主要是水果、蔬菜摄入不足，缺乏体育锻炼。肥胖主要是由于能量摄入过多造成的，能量摄入超过机体处理负荷时，就会导致相应的病理生理改变，如高血糖、高血脂、脂肪肝等。如今市面上有多种减肥药，其减肥效果虽然明显，但存在很多问题如副作用大、依赖性强等。因此，为了避免减肥药给身体带来的副作用，开发出辅助降脂减肥的保健食品具有非常重要的意义。
海藻产量丰富、易获得，是一种具有食药两用价值的海洋生物资源。近年来关于海藻的研究越来越多，研究表明来自海藻的许多天然产物具有抗炎、降脂减肥、降血糖等生物活性。例如褐藻中的羊栖菜，关于其活性成分及相应的生理功能已有较为广泛的研究；其中有文章提到羊栖菜中的岩藻黄质提取物可以通过调节血糖代谢途径，起到降低肥胖小鼠体重的效果，但笔者通过实验验证时发现，羊栖菜仅能使附睾脂肪显著减少，对皮下脂肪没有作用，单一食用效果不佳，所以需要一种配方食品来补足羊栖菜在减脂方面的不足。
发明内容
本发明要解决的技术问题是羊栖菜仅能使附睾脂肪显著减少，对皮下脂肪没有作用，单一食用效果不佳，所以需要一种配方食品来补足羊栖菜在减脂方面的不足。
为解决上述问题，本发明提供一种辅助降脂减肥的海藻果蔬配方，通过在羊栖菜中复配姜黄提取物和石榴皮提取物，充分利用海藻和果蔬中的天然活性物质，实现辅助降脂减肥的效果，并进一步提高自然资源的利用率。同时，海藻果蔬的天然属性会极大降低合成物质带来的毒副作用，其来源的天然产物安全无毒、无害，并且能够达到辅助降脂减肥的目的，能够改善人群的健康状况。
为达到上述目的，本发明具体通过以下技术方案实现：一种辅助降脂减肥的配方，包括以下质量百分比的组分：羊栖菜95-96％；姜黄提取物2-3％；石榴皮提取物1-2％。
羊栖菜(Sargassum fusiforme)是褐藻门马尾藻科马尾藻属植物，在我国沿海地带均有分布，是一种低脂低热、高蛋白、高膳食纤维和含丰富矿物元素的天然食品。研究发 现羊栖菜具有广泛的生物活性，如抗氧化、抗癌和减肥作用等。有研究表明羊栖菜中岩藻黄质提取物具有良好的减肥作用，其作用机理还待研究，但实验结果表明可能是通过调节血糖代谢途径，从而降低血糖含量，实现减肥的作用。
姜黄素(Curcumin)是从姜科植物姜黄中提取的一种常见的食用色素，具有抗氧化、抗炎等功能。研究表明姜黄素还可以调节体内脂质代谢，显著降低血清和肝脏中的胆固醇含量。而脂质代谢时部分产物会通过糖酵解或产生糖而进入血糖代谢，姜黄素对于羊栖菜的协同作用可能是在于通过脂质代谢的调节，将体内的脂肪，特别是皮下脂肪分解，再通过血糖代谢途径进行代谢，从而解决羊栖菜不能作用皮下脂肪的问题。本发明所用姜黄提取物源自陕西藤迈生物科技有限公司，主要成分：姜黄素，含量约为20％。
从石榴皮中提取的多酚类物质安石榴苷被人体吸收后，可以分解为鞣花酸，其抗氧化性优良，且在抗炎抗癌等方面具有重要的作用，同时有研究表明安石榴苷也具有降脂减肥的功效。安石榴苷在配方中的作用，一方面可能是通过改善炎性反应和肝脏氧化应激，加强肝脏对胆固醇的转化，辅助姜黄素的降胆固醇作用，从而影响脂质代谢；另一个方面可能是改善胰岛素抵抗，使细胞葡萄糖摄取能力下降，从而辅助羊栖菜改善血糖代谢，从而实现辅助减脂的最佳效果。本发明所用石榴皮提取物源自陕西藤迈生物科技有限公司，主要成分：安石榴苷，含量约为20％。
进一步的，所述配方包括以下质量百分比的组分：羊栖菜95.88％；姜黄提取物2.68％；石榴皮提取物1.44％。
以体外糖脂代谢关键酶α-葡萄糖苷酶和胰脂肪酶抑制率为评价指标，抑制率越高效果越好。通过单因素试验和D优化响应面分析，得出最优配方。单因素试验结果如图1所示。在单因素试验的基础上，对配方进行响应面分析，试验因素与水平设计见表1，试验分组及结果如表2所示。对于α-葡萄糖苷酶抑制率和胰脂肪酶抑制率两个响应值，模型的P值均小于0.05，判断模型显著；模型失拟项p值均大于0.05，说明模型失拟项不显著。两个响应值的模型相关系数R
2分别为0.99、0.94，校正后R
2分别为0.97、0.82，表示模型相关度良好；模型的变异系数均小于10％，说明模型对响应值的置信度良好，该模型可以较好地反应试验的真实性。对响应面试验的数据进行分析处理，结果如表3和图1所示。由配方对两种酶的抑制效果可以看出，A1水平(羊栖菜水提物)时，配方对两种酶的抑制效果优于A2和A3水平；B3水平(姜黄素)时，配方对两种酶的抑制效果优于B1和B2；C3水平(安石榴苷)时，配方对两种酶的抑制效果优于C1和C2。经Design-Expert 8.0.6软件分析得出最佳配方为：羊栖菜水提物配比为150，姜黄 素配比为6；安石榴苷配比为3；相应的模型预测α-葡萄糖苷酶抑制率为45.98％，胰脂肪酶抑制率为73.88％。选取预测所得的最佳配比进行复配，检测复配配方2种酶活性抑制率，配方α-葡萄糖苷酶抑制率为47.77±2.15％，胰脂肪酶抑制率为74.18±0.46％，实际值与预测值相近，说明该模型能够较好地预测配方最佳配比。
由此确定的最优配比为羊栖菜水提物∶姜黄素∶安石榴苷＝150∶6∶3(w/w/w)。此配方中姜黄素纯度为95％，安石榴苷纯度为98％。因为配方成分均为高纯度的功能因子，没有食用的习惯，不是新食品原料，不能直接用于保健食品。据此制定保健食品级配方，其中羊栖菜水提物对应羊栖菜(羊栖菜水提物含量约为15％)，姜黄素对应姜黄提取物(姜黄素含量约为20％)，安石榴苷对应石榴皮提取物(安石榴苷含量约为20％)。即羊栖菜∶姜黄提取物∶石榴皮提取物＝1000∶28∶15(w/w/w)。因此最佳配方组成为：羊栖菜95.88％；姜黄提取物2.68％；石榴皮提取物1.44％。
表1响应面设计因素与水平
表2响应面试验设计及结果(n＝3)
表3响应面试验数据处理结果
注：A：羊栖菜水提物配比；B：姜黄素配比；C：安石榴苷配比；K1：1水平；K2：2水平；K3：3水平。
进一步的，所述配方所用的姜黄提取物的姜黄素含量为20％，石榴皮提取物的安石榴苷含量为20％。
进一步的，一种辅助降脂减肥配方的应用，按照配方质量百分比称取各组分，按照5％的比例添加入饮食中。根据美国FDA标准规定饲料中受试物的添加量不得超过5％，以不影响正常饮食结构为目的。因此按照5％的比例添加入饮食中，不影响正常饮食结构的情况下又可发挥辅助降血脂、缓解肥胖的作用。
本发明的有益效果在于：
本发明以羊栖菜为主要原料，利用海藻果蔬优良自然资源研发了一种海藻果蔬复配配方，对高脂饮食诱导的肥胖小鼠体重增长有显著的抑制作用，能够减少小鼠体内脂质 积累，降低血脂水平，从而达到辅助降血脂、缓解肥胖的目的；并且实现了羊栖菜的高值化利用。
图1海藻果蔬复配单因素和响应面分析。
图2各实验组小鼠体重变化对比图。
图3各实验组小鼠体内脂质积累情况对比图。
图4各实验组小鼠血脂水平对比图。
为使本发明实施例的目的、技术方案和优点更加清楚，下面对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
实施例1：
本实施例的配方为羊栖菜95％；姜黄提取物3％；石榴皮提取物2％。按照配方质量百分比称取各组分，混合后以5％添加量加入饮食中。
实施例2：
本实施例的配方为羊栖菜96％；姜黄提取物3％；石榴皮提取物1％。按照配方质量百分比称取各组分，混合后以5％添加量加入饮食中。
实施例3：
本实施例的配方为羊栖菜96％；姜黄提取物2％；石榴皮提取物2％。按照配方质量百分比称取各组分，混合后以5％添加量加入饮食中。
实施例4：
本实施例的配方为羊栖菜95.5％；姜黄提取物2.5％；石榴皮提取物2％。按照配方质量百分比称取各组分，混合后以5％添加量加入饮食中。
实施例5：
本实施例的配方为羊栖菜95.88％；姜黄提取物2.68％；石榴皮提取物1.44％。按照配方质量百分比称取各组分，混合后以5％添加量加入饮食中。
对比实施例：采用实施例5的配方做以下实验。
(1)动物实验：高脂饮食诱导的肥胖小鼠模型建立与分组。C57BL/6小鼠适应性喂养1周，按体重随机分为6组，每组10只，即正常组(Control)，肥胖模型组(Model)，羊栖 菜组(S)，羊栖菜与石榴皮提取物复配组(SP)，羊栖菜与姜黄提取物复配组(ST)，三组分配方组(STP)。正常组小鼠给予10％低脂对照饲料(D14060603)，其余5组给予45％高脂饲料(D14060606)，小鼠自由摄食9周。室内温度21℃-23℃，相对湿度40％-55％，空气流通，光照时间12h。9周后，按照表4所示给予各组小鼠饲料，持续喂养4周。饲养期间每周称1次体重，每2天记录1次摄食量。实验结束后，称体重，处死，解剖取相应内脏称重并记录，并保存于-80℃，备用。
表4组别与饲料配方
实验结果：
(1)统计各实验组小鼠饲养期间体重变化情况。结果如图2所示，高脂饮食导致小鼠体重显著增加，Lee指数显著高于正常组，表明长期的高脂饮食导致小鼠肥胖。而摄入配方后(STP组)，小鼠体重增长缓慢，体重增长和Lee指数均显著低于模型组。将配方组(STP)与S、SP和ST组分别进行比较后，发现羊栖菜与姜黄提取物和/或石榴皮提取物复配后均可延缓小鼠体重增长。但三组分复配的效果最佳，与模型组相比差异达到显著性。既优于羊栖菜单一成分，也优于两种成分(羊栖菜与姜黄提取物或石榴皮提取物复配)，对肥胖小鼠具有一定的延缓体重增长的作用。
(2)称量小鼠各脂肪组织的重量并计算体脂率。结果如图3所示，高脂饮食导致小鼠脂肪组织：附睾脂肪、皮下脂肪、肾周脂肪积累量显著增加，体脂率显著高于正常组。本发明配方则显著减少了附睾脂肪和皮下脂肪的积累量，显著降低了体脂率。将配方组(STP)与S、SP和ST组分别进行比较后，发现羊栖菜与姜黄提取物和/或石榴皮 提取物复配后均减少了附睾脂肪和皮下脂肪的积累量，降低了体脂率，且达到显著性。相比之下，羊栖菜组仅附睾脂肪显著减少，三组分复配的效果要明显优于羊栖菜单一成分。同时也优于两种成分(羊栖菜与姜黄提取物或石榴皮提取物复配)，说明配方具有辅助肥胖小鼠减肥的作用。
(3)测定各实验组小鼠的血脂水平，结果如图4所示。羊栖菜与姜黄提取物和/或石榴皮提取物复配后相应地降低了小鼠血清总胆固醇(TC)水平，虽然未达到显著水平，但依照羊栖菜单一成分、两种成分复配、三组分配方的次序具有逐渐降低的趋势。本发明配方能够显著降低肥胖小鼠血液中甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)的含量，能够将LDL-C∶HDL-C比例恢复到正常水平，且效果优于羊栖菜单一成分和两种成分复配(羊栖菜与姜黄提取物或石榴皮提取物复配)。说明本发明配方能够辅助降低肥胖小鼠的血脂水平。
以上所述，仅是本发明的较佳实施例，并非是对本发明作其它形式的限制，任何熟悉本专业的技术人员可以利用上述技术内容加以变更或改型为等同变化的等效实施例。但是凡是未脱离本发明技术方案内容，依据本发明的技术实质对以上实施例所作的任何简单修改、等同变化与改型，仍属于本发明技术方案的保护范围。
Claims (4)
- 一种辅助降脂减肥的配方，其特征在于包括以下质量百分比的组分：羊栖菜95-96％；姜黄提取物2-3％；石榴皮提取物1-2％。
- 如权利要求1所述的辅助降脂减肥的配方，其特征在于包括以下质量百分比的组分：羊栖菜95.88％；姜黄提取物2.68％；石榴皮提取物1.44％。
- 如权利要求1或2所述的辅助降脂减肥的配方，其特征在于：所述配方所用的姜黄提取物的姜黄素含量为20％，石榴皮提取物的安石榴苷含量为20％。
- 一种权利要求1中的辅助降脂减肥的配方的应用，其特征在于：按照配方质量百分比称取各组分，按照5％的比例添加入饮食中。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010262858.0A CN111449243A (zh) | 2020-04-07 | 2020-04-07 | 一种辅助降脂减肥的海藻果蔬配方 |
| CN202010262858.0 | 2020-04-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2021203661A1 true WO2021203661A1 (zh) | 2021-10-14 |
Family
ID=71670720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2020/120760 WO2021203661A1 (zh) | 2020-04-07 | 2020-10-14 | 一种辅助降脂减肥的海藻果蔬配方 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN111449243A (zh) |
| WO (1) | WO2021203661A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111449243A (zh) * | 2020-04-07 | 2020-07-28 | 中国海洋大学 | 一种辅助降脂减肥的海藻果蔬配方 |
| CN113896751B (zh) * | 2021-11-19 | 2023-05-12 | 中国农业科学院都市农业研究所 | 安石榴苷纯化方法及其在制备α-葡萄糖苷酶抑制剂中的应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080206275A1 (en) * | 2006-12-08 | 2008-08-28 | Zakir Ramazanov | Composition for treating obesity and method of using the same |
| US20080233209A1 (en) * | 2007-03-22 | 2008-09-25 | Polifenoles Naturales, Sl | Composition and method of use for the treatment of metabolic syndrome and inflammation |
| CN102334688A (zh) * | 2011-07-21 | 2012-02-01 | 秦皇岛大惠生物技术有限公司 | 一种具有减脂功能的保健食品 |
| WO2019178689A1 (en) * | 2018-03-20 | 2019-09-26 | Exerkine Corporation | Weight management composition |
| CN111449243A (zh) * | 2020-04-07 | 2020-07-28 | 中国海洋大学 | 一种辅助降脂减肥的海藻果蔬配方 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101721403A (zh) * | 2008-10-16 | 2010-06-09 | 北京绿色金可生物技术股份有限公司 | 岩藻黄素在减肥方面的应用 |
| CN109717426A (zh) * | 2018-12-24 | 2019-05-07 | 江苏辰星药业股份有限公司 | 一种降血糖保健食品及其制备方法 |
-
2020
- 2020-04-07 CN CN202010262858.0A patent/CN111449243A/zh active Pending
- 2020-10-14 WO PCT/CN2020/120760 patent/WO2021203661A1/zh active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080206275A1 (en) * | 2006-12-08 | 2008-08-28 | Zakir Ramazanov | Composition for treating obesity and method of using the same |
| US20080233209A1 (en) * | 2007-03-22 | 2008-09-25 | Polifenoles Naturales, Sl | Composition and method of use for the treatment of metabolic syndrome and inflammation |
| CN102334688A (zh) * | 2011-07-21 | 2012-02-01 | 秦皇岛大惠生物技术有限公司 | 一种具有减脂功能的保健食品 |
| WO2019178689A1 (en) * | 2018-03-20 | 2019-09-26 | Exerkine Corporation | Weight management composition |
| CN111449243A (zh) * | 2020-04-07 | 2020-07-28 | 中国海洋大学 | 一种辅助降脂减肥的海藻果蔬配方 |
Non-Patent Citations (5)
| Title |
|---|
| TAN XIN, CHENG ANWEI SUN JINYUE GU CHUNMEI LIU CHAO GUO XU: "Research Progress on Effects Mechanisms of Polyphenols on Adipocytes", FOOD AND NUTRITION IN CHINA, vol. 23, no. 9, 31 December 2017 (2017-12-31), pages 58 - 61, XP055857026 * |
| WANG CAISHENG, TAN ZHIWEN QIAN GUOYING ZHOU KAILI DING HAOMIAO: "Anti-obesity Effect of Sargassum Fucoxanthin Extract on Diet-induced Obese Mice", PHARMACEUTICAL BIOTECHNOLOGY, 31 December 2016 (2016-12-31), pages 328 - 331, XP055857037, ISSN: 1005-8915, DOI: 10.19526/j.cnki.1005-8915.2016.04.011 * |
| WU YUELIN, ZHAN XIN: "The Functional Properties of Fucoxanthin and Its Application in Food Industry", FOOD RESEARCH AND DEVELOPMENT, vol. 33, no. 10, 31 October 2012 (2012-10-31), pages 203 - 206, XP055857035 * |
| YUN, J.W.: "Possible anti-obesity therapeutics from nature - A review", PHYTOCHEMISTRY, ELSEVIER, AMSTERDAM , NL, vol. 71, no. 14-15, 1 October 2010 (2010-10-01), Amsterdam , NL , pages 1625 - 1641, XP027264690, ISSN: 0031-9422 * |
| ZHOU, SAINAN ET AL.: "Response Surface Methodology to Optimize a Seaweed and Fruit-vegetable Compound Formula That Assists in Reducing Blood Sugar and Lipid", FOOD SCIENCE, 25 September 2020 (2020-09-25) * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111449243A (zh) | 2020-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103989059B (zh) | 富含功能肽铁锌营养面条 | |
| Awang et al. | Anti-obesity property of the brown seaweed, Sargassum polycystum using an in vivo animal model | |
| WO2021203661A1 (zh) | 一种辅助降脂减肥的海藻果蔬配方 | |
| CN102406860A (zh) | 预防和治疗糖尿病的组合物、其制备方法及应用 | |
| CN105747235B (zh) | 一种能改善代谢综合征症状的饮食组合物 | |
| Wu et al. | Hypoglycemic effect of okra aqueous extract on streptozotocin-induced diabetic rats | |
| CN104721652A (zh) | 乳酸菌发酵大麦粉及其制备方法与用途 | |
| CN103355619B (zh) | 一种滇橄榄葛根保健食品 | |
| de Almeida et al. | Improvement of physiological parameters of rats subjected to hypercaloric diet, with the use of Pereskia grandifolia (Cactaceae) leaf flour | |
| CN111802536B (zh) | 一种大黄鱼雌鱼饲料添加剂及其制备方法与应用 | |
| CN102113652A (zh) | 一种适合“五高”代谢综合症人群的特膳挤压米及其制备方法 | |
| CN100506088C (zh) | 延缓衰老的保健组合物 | |
| CN107625034B (zh) | 一种糖尿病患者代餐粉及其制备方法 | |
| CN1301665C (zh) | 调血脂护肝保健食品 | |
| CN102511690A (zh) | 一种抗肉鸡热应激的饲料配方 | |
| CN104397587A (zh) | 一种高含量慢消化淀粉(sds)的天然富硒米片的制备方法 | |
| CN104012848A (zh) | 一种虾蛄保健保鲜年糕及其制备方法 | |
| CN114424818A (zh) | 一种基于苹果的低卡路里代餐营养棒及其制备方法 | |
| JP4907280B2 (ja) | リパーゼ阻害剤 | |
| CN114391653A (zh) | 一种用于减肥的运动营养片及其制备方法 | |
| CN103355665B (zh) | 一种用于辅助降血糖的组合物 | |
| CN112890066A (zh) | 一种调血脂、抗疲劳、增强免疫力的固体饮料及其应用 | |
| CN106071778A (zh) | 一种金钗石斛叶面条制品的制作方法 | |
| CN109170573A (zh) | 一种降血脂的保健面条 | |
| CN112704713B (zh) | 一种改善化疗所致肠粘膜炎的卡帕藻谷物粉配方 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20930248 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 20930248 Country of ref document: EP Kind code of ref document: A1 |